T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment

• DOI: 10.1371/journal.pone.0043746
• Publication Date: 2012-08-20T21:14:09Z
• Authors: Keith R. Miller; Akiko Koide; Brenda Leung; Jonathan Fitzsimmons; Bryan Yoder; Hong Yuan; Michael Jay; Sachdev S. Sidhu; Shohei Koide; Edward J. Collins
• Keywords: 0301 basic medicine; 570; Receptor, ErbB-2; Science; Q; R; Receptors, Antigen, T-Cell; 610; CHO Cells; 3. Good health; Mice; 03 medical and health sciences; 0302 clinical medicine; Cell Line, Tumor; Cricetinae; HLA-A2 Antigen; Medicine; Animals; Humans; Peptides; Immunoglobulin Fragments; Research Article; Protein Binding

A major difficulty in treating cancer is the inability to differentiate between normal and tumor cells. The immune system differentiates tumor from normal cells by T cell receptor (TCR) binding of tumor-associated peptides bound to Major Histocompatibility Complex (pMHC) molecules. The peptides, derived from the tumor-specific proteins, are presented by MHC proteins, which then serve as cancer markers. The TCR is a difficult protein to use as a recombinant protein because of production issues and has poor affinity for pMHC; therefore, it is not a good choice for use as a tumor identifier outside of the immune system. We constructed a synthetic antibody-fragment (Fab) library in the phage-display format and isolated antibody-fragments that bind pMHC with high affinity and specificity. One Fab, fE75, recognizes our model cancer marker, the Human Epidermal growth factor Receptor 2 (HER2/neu) peptide, E75, bound to the MHC called Human Leukocyte Antigen-A2 (HLA-A2), with nanomolar affinity. The fE75 bound selectively to E75/HLA-A2 positive cancer cell lines in vitro. The fE75 Fab conjugated with 64Cu selectively accumulated in E75/HLA-A2 positive tumors and not in E75/HLA-A2 negative tumors in an HLA-A2 transgenic mouse as probed using positron emission tomography/computed tomography (PET/CT) imaging. Considering that hundreds to thousands of different peptides bound to HLA-A2 are present on the surface of each cell, the fact that fE75 arrives at the tumor at all shows extraordinary specificity. These antibody fragments have great potential for diagnosis and targeted drug delivery in cancer.